Top

Published in:

Open Access 01-12-2014 | Review

Novel agents and strategies for overcoming EGFR TKIs resistance

Authors: Fei-Yu Niu, Yi-Long Wu

Published in: Experimental Hematology & Oncology | Issue 1/2014

Abstract

Since the recognition of epidermal growth factor receptor (EGFR) as a therapeutic target, EGFR tyrosine kinase inhibitors (TKIs) have been used in lung cancer patients with EGFR mutations, which has been a major breakthrough for lung cancer treatment.. The progression-free survival (PFS) of patients with EGFR mutations treated with EGFR TKIs is significantly prolonged compared with that of patients who underwent standard chemotherapy. However, all patients who initially respond to EGFR TKIs eventually develop acquired resistance (AR). Many small molecule agents and monoclonal antibodies (McAb) targeting signaling pathways are potential therapeutic regimens for overcoming resistance, and various therapeutic strategies are used in clinical practice. Here we review the novel agents and therapeutic strategies for overcoming AR to EGFR TKIs.

Available only for authorised users

Hung JJ, Hsueh CT, Chen KH, Hsu WH, Wu YC: Clinical significance of E2F1 protein expression in non-small cell lung cancer. Exp Hematol Oncol 2012,1(1):18. 10.1186/2162-3619-1-18PubMedCentralPubMedCrossRef

Cheng H, An SJ, Dong S, Zhang YF, Zhang XC, Chen ZH, Jian-Su , Wu YL: Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib. J Hematol Oncol 2011, 4–5.

Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. J Hematol Oncol 2011, 4–16.

Xu C, Zhou Q, Wu YL: Can EGFR-TKIs be used in first line treatment for advanced non-small cell lung cancer based on selection according to clinical factors? - A literature-based meta-analysis. J Hematol Oncol 2012, 5–62.

Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors[J]. Oncogene 2009,28(Suppl 1):S24-S31.PubMedCentralPubMedCrossRef

Katzel JA, Fanucchi MP, Li Z: Recent advances of novel targeted therapy in non-small cell lung cancer. J Hematol Oncol 2009, 2–2.

Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, et al.: Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial[J]. Lancet Oncol 2012,13(5):528–538. 10.1016/S1470-2045(12)70087-6PubMedCrossRef

Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K, et al.: LUX-lung 4: a phase II trial of afatinib in patients with advanced Non-small-cell lung cancer Who progressed during prior treatment with Erlotinib, Gefitinib, or both[J]. J Clin Oncol 2013,31(27):3335–41. 10.1200/JCO.2012.45.0981PubMedCrossRef

Martin H, Schuler DP, Yang JCH, Kim J, De Marinis F, Chen Y, Zhou C, Bennouna J, Liu X, Feng JF, et al.: Interimanalysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy[J]. J Clin Oncol 2012., 30: abstr 7557

10.

Campbell A, Reckamp KL, Camidge DR, Giaccone G, Gadgeel SM, Khuri FR, Engelman JA, Denis LJ, O'Connell JP, Janne PA: PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): a phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E). J Clin Oncol 2010,28(5s):7596. suppl; abstr

11.

Takahashi T, Boku N, Murakami H, Naito T, Tsuya A, Nakamura Y, Ono A, Machida N, Yamazaki K, Watanabe J, et al.: Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs 2012,30(6):2352–2363. 10.1007/s10637-011-9789-zPubMedCentralPubMedCrossRef

12.

Janne PA, Boss DS, Camidge DR, Britten CD, Engelman JA, Garon EB, Guo F, Wong S, Liang J, Letrent S, et al.: Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res 2011,17(5):1131–1139. 10.1158/1078-0432.CCR-10-1220PubMedCentralPubMedCrossRef

13.

Sequist LV, Soria JC, Gadgeel SM, Wakelee HA, Camidge DR: First-in-human evaluation of CO-1686, an irreversible, selective, and potent tyrosine kinase inhibitor of EGFR T790M[J]. J Clin Oncol 2013, 31: 2524. suppl; abstrCrossRef

14.

Ranson M, Pao W, Kim DW: AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFR+) and resistance (T790M) mutations in advanced NSCLC The AURA study. J Thorac Oncol 2013, 11–034. suppl; abstr P1.11

15.

Robinson KW, Sandler AB: The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist 2013,18(2):115–122. 10.1634/theoncologist.2012-0262PubMedCentralPubMedCrossRef

16.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007,316(5827):1039–1043. 10.1126/science.1141478PubMedCrossRef

17.

Vashishtha A, Patel PH, Yu W, Bothos JG, Simpson J, Maneatis T, Doessegger L, Peterson AC, Clement-Duchene C, Robinet G, et al.: Safety data and patterns of progression in met diagnostic subgroups in OAM4558g; A phase II trial evaluating MetMAb in combination with erlotinib in advanced NSCLC. J Clin Oncol 2011, 29: 7604. suppl; abstr

18.

Sequist LV, Von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, et al.: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011,29(24):3307–3315. 10.1200/JCO.2010.34.0570PubMedCrossRef

19.

Yano S, Yamada T, Takeuchi S, Tachibana K, Minami Y, Yatabe Y, Mitsudomi T, Tanaka H, Kimura T, Kudoh S, et al.: Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort. J Thorac Oncol 2011,6(2):2011–2017.PubMedCrossRef

20.

Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, et al.: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res 2008,68(22):9479–9487. 10.1158/0008-5472.CAN-08-1643PubMedCrossRef

21.

Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S: The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer 2013,133(2):505–513. 10.1002/ijc.28034PubMedCrossRef

22.

Koizumi H, Yamada T, Takeuchi S, Nakagawa T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Yano S: Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis. J Thorac Oncol 2012,7(7):1078–1085. 10.1097/JTO.0b013e3182519a2cPubMedCrossRef

23.

Johnson ML, Hart EM, Rademaker A, Weitner BB, Urman A, Simm HD, Fountas LM, Worden R, Patel JD, Miller VA, et al.: A phase II study of HSP90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR TKIs). J Clin Oncol 2013, 8036. suppl; abstr

24.

Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cosper AK, et al.: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011,3(75):26r-75r.CrossRef

25.

Tan DS, Lim KH, Tai WM, Ahmad A, Pan S, Ng QS, Ang M, Gogna A, Ng YL, Tan BS, et al.: A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib (gef) in EGFR TKI-resistant NSCLC. J Clin Oncol 2013, 8107. suppl; abstr

26.

Yu HA, Arcila ME, Rekhtman N, Sima CS, Zakowski MF, Pao W, Kris MG, Miller VA, Ladanyi M, Riely GJ: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013,19(8):2240–2247. 10.1158/1078-0432.CCR-12-2246PubMedCentralPubMedCrossRef

27.

Mack PC, Farneth N, Mahaffey C, Lara P, Gandara DR: Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). J Clin Oncol 2011, 7573. suppl; abstr

28.

Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al.: mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One 2013,8(5):e62104. 10.1371/journal.pone.0062104PubMedCentralPubMedCrossRef

29.

Dong S, Zhang X, Cheng H, Guo A, Zhu J, Yang S, Wu YL: Effect of everolimus and gefitinib on PI3K/akt/mTOR and raf/MEK/ERK pathways in NSCLC cells. J Clin Oncol 2010, e13654. suppl; abstr

30.

Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, et al.: Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol 2010,5(10):1623–1629. 10.1097/JTO.0b013e3181ec1531PubMedCentralPubMedCrossRef

31.

Fei SJ, Zhang XC, Dong S, Cheng H, Zhang YF, Huang L, Zhou HY, Xie Z, Chen ZH, Wu YL: Targeting mTOR to overcome epidermal growth factor receptor tyrosine kinase inhibitor resistance in Non-small cell lung cancer cells. PLoS One 2013,8(7):e69104. 10.1371/journal.pone.0069104PubMedCentralPubMedCrossRef

32.

Remon J, Moran T, Majem M, Reguart N, Dalmau E, Marquez-Medina D, Lianes P: Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins. Cancer Treat Rev 2014,40(1):93–101. 10.1016/j.ctrv.2013.06.002PubMedCrossRef

33.

Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC: MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol 2013,7(1):112–120. 10.1016/j.molonc.2012.09.002PubMedCrossRef

34.

Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ: Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011,17(19):6298–6303. 10.1158/1078-0432.CCR-11-1468PubMedCentralPubMedCrossRef

35.

Goldberg SB, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV: Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI). J Clin Oncol 2012, 7524. suppl; abstr

36.

Yang JJ, Chen HJ, Yan HH, Zhang XC, Zhou Q, Su J, Wang Z, Xu CR, Huang YS, Wang BC, et al.: Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer. Lung Cancer-J Iaslc 2013,79(1):33–39. 10.1016/j.lungcan.2012.09.016CrossRef

Title: Novel agents and strategies for overcoming EGFR TKIs resistance
Authors: Fei-Yu Niu
Yi-Long Wu
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Experimental Hematology & Oncology / Issue 1/2014
Electronic ISSN: 2162-3619
DOI: https://doi.org/10.1186/2162-3619-3-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Do novo del(9)(p13) in a childhood T-cell prolymphocytic leukemia as sole abnormality

Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial

Cohesin mutations in myeloid malignancies: underlying mechanisms

Ibrutinib for B cell malignancies

Vitamin D3 potentiates the antitumorigenic effects of arsenic trioxide in human leukemia (HL-60) cells

Activation of Akt at T308 and S473 in alcohol, tobacco and HPV-induced HNSCC: is there evidence to support a prognostic or diagnostic role?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer